A subscription to JoVE is required to view this content. Sign in or start your free trial.
* These authors contributed equally
The following procedure describes a method for spatial and temporal control of melanocytic tumor initiation in murine dorsal skin, using a genetically engineered mouse model. This protocol describes macroscopic as well as microscopic cutaneous melanoma initiation.
Cutaneous melanoma is well known as the most aggressive skin cancer. Although the risk factors and major genetic alterations continue to be documented with increasing depth, the incidence rate of cutaneous melanoma has shown a rapid and continuous increase during recent decades. In order to find effective preventative methods, it is important to understand the early steps of melanoma initiation in the skin. Previous data has demonstrated that follicular melanocyte stem cells (MCSCs) in the adult skin tissues can act as melanoma cells of origin when expressing oncogenic mutations and genetic alterations. Tumorigenesis arising from melanoma-prone MCSCs can be induced when MCSCs transition from a quiescent to active state. This transition in melanoma-prone MCSCs can be promoted by the modulation of either hair follicle stem cells' activity state or through extrinsic environmental factors such as ultraviolet-B (UV-B). These factors can be artificially manipulated in the laboratory by chemical depilation, which causes transition of hair follicle stem cells and MCSCs from a quiescent to active state, and by UV-B exposure using a benchtop light. These methods provide successful spatial and temporal control of cutaneous melanoma initiation in the murine dorsal skin. Therefore, these in vivo model systems will be valuable to define the early steps of cutaneous melanoma initiation and could be used to test potential methods for tumor prevention.
Melanoma, the malignant form of melanocytic tumors, is the most aggressive cancer in the skin with cutaneous melanoma responsible for the majority of skin cancer deaths1. In the United States, melanoma is commonly diagnosed; it is projected to be the 5th to 6th most common cancer type among the estimated new cancer cases in 20182. Furthermore, while overall cancer incidences have shown the trend of gradual reduction in recent decades, cutaneous melanoma incidence rates during the last few decades demonstrate a continuous and rapid increase in both genders2.
All animal procedures are performed in accordance with Cornell University Institutional Animal Care and Use Committee (IACUC).
1. Preparation
Cutaneous melanoma initiation induced by chemical depilation
The procedure of chemical depilation is depicted in Figure 2. When mice are 7-weeks postnatal, their dorsal skin is in telogen. During telogen, hair follicle stem cells and MCSCs are known to be in a quiescent, resting state. The skin should show no significant hair growth after shaving. On the other hand, chemical de.......
Hallmark genetic alterations frequently found in cutaneous melanoma tumors have been well described13. The most dominant driver mutation is BrafV600E, and a genetically engineered mouse model for BrafV600E-mediated melanoma was generated by the Bosenberg group14 and deposited in the Jackson Laboratory. Using this mouse model, our recent study demonstrated the requirement of cellular activation of tumor-prone MCSCs for the significant .......
The authors declare no conflict of interest.
This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs, through the Peer Reviewed Cancer Research Program under award W81XWH-16-1-0272. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense. This work was also supported by a seed grant from the Cornell Stem Cell Program to A.C. White. H. Moon was supported by the Cornell Center for Vertebrate Genomics Scholar Program.
....Name | Company | Catalog Number | Comments |
Tamoxifen | Sigma | T5648-1G | For systemic injection |
Tamoxifen | Cayman Chemical | 13258 | For systemic injection |
Corn oil | Sigma | 45-C8267-2.5L-EA | |
4OH-tamoxifen | Sigma | H7904-25MG | For topical treatment |
26g 1/2" needles | various | Veterinary grade | |
1 mL syringe | various | Veterinary grade | |
Pet hair trimmer | Wahl | 09990-502 | |
Hair removal cream | Nair | n/a | Available at most drug stores |
Cotton swabs | various | ||
Ultraviolet light bulb | UVP | 95-0042-08 | model XX-15M midrange UV lamp |
200 proof ethanol | various | pure ethanol | |
Histoplast PE | Fisher Scientific | 22900700 | paraffin pellets |
Neutral Buffered Formalin, 10% | Sigma | HT501128-4L | |
Clear-Rite 3 | Thermo Scientific | 6901 | xylene substitute |
O.C.T. Compound | Thermo | 23730571 | |
Tissue Cassette | Sakura | 89199-430 | for FFPE processing |
Cryomolds | Sakura | 4557 | 25 x 20 mm |
FFPE metal mold | Leica | 3803082 | 24 x 24 mm |
Isoflurane | various | Veterinary grade | |
Anesthesia inhalation system | various | Veterinary grade | |
Fine scissor | FST | 14085-09 | Straight, sharp/sharp |
Fine scissor | FST | 14558-09 | Straight, sharp/sharp |
Metzenbaum | FST | 14018-13 | Straight, blunt/blunt |
Forcep | FST | 11252-00 | Dumont #5 |
Forcep | FST | 11018-12 | Micro-Adson |
Tyr-CreER; LSL-BrafV600E; Pten-f/f | Jackson Labs | 13590 | |
LSL-tdTomato | Jackson Labs | 007914 | ai14 |
Cre-1 | n/a | GCATTACCGGTCGATGCAACGAGTGATGAG | |
Cre-2 | n/a | GAGTGAACGAACCTGGTCGAAATCAGTGCG | |
Braf-V600E-1 | n/a | TGAGTATTTTTGTGGCAACTGC | |
Braf-V600E-2 | n/a | CTCTGCTGGGAAAGCGGC | |
Kras-G12D-1 | n/a | AGCTAGCCACCATGGCTTGAGTAAGTCTGCA | |
Kras-G12D-2 | n/a | CCTTTACAAGCGCACGCAGACTGTAGA | |
Pten-1 | n/a | ACTCAAGGCAGGGATGAGC | |
Pten-2 | n/a | AATCTAGGGCCTCTTGTGCC | |
Pten-3 | n/a | GCTTGATATCGAATTCCTGCAGC | |
tdTomato-1 | n/a | AAGGGAGCTGCAGTGGAGTA | |
tdTomato-2 | n/a | CCGAAAATCTGTGGGAAGTC | |
tdTomato-3 | n/a | GGCATTAAAGCAGCGTATCC | |
tdTomato-4 | n/a | CTGTTCCTGTACGGCATGG |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved